Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotech company developing curative targeted cell therapies for autoimmune diseases, has announced its participation in four major investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 10), and H.C. Wainwright Global Investment Conference (Sept 10). Webcasted fireside chats will be available on the company's website for 30 days.
Cabaletta Bio (Nasdaq: CABA), società biotech in fase clinica che sviluppa terapie cellulari mirate volte a curare le malattie autoimmuni, ha annunciato la sua partecipazione a quattro importanti conferenze per investitori a settembre 2025.
L'azienda presenterà al Cantor Global Healthcare Conference (3 settembre), al Wells Fargo Healthcare Conference (4 settembre), al Morgan Stanley Global Healthcare Conference (10 settembre) e all'H.C. Wainwright Global Investment Conference (10 settembre). Le conversazioni in formato fireside chat saranno trasmesse via webcast sul sito della società e rimarranno disponibili per 30 giorni.
Cabaletta Bio (Nasdaq: CABA), una empresa biotecnológica en fase clínica que desarrolla terapias celulares dirigidas con potencial curativo para enfermedades autoinmunes, ha anunciado su participación en cuatro importantes conferencias para inversores en septiembre de 2025.
La compañía presentará en la Cantor Global Healthcare Conference (3 de septiembre), en la Wells Fargo Healthcare Conference (4 de septiembre), en la Morgan Stanley Global Healthcare Conference (10 de septiembre) y en la H.C. Wainwright Global Investment Conference (10 de septiembre). Las charlas tipo fireside chat se emitirán por webcast en la web de la compañía y estarán disponibles durante 30 días.
Cabaletta Bio (Nasdaq: CABA)는 자가면역 질환을 치료할 수 있는 표적 세포 치료제를 개발 중인 임상 단계의 바이오기업으로, 2025년 9월에 열리는 네 곳의 주요 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 Cantor Global Healthcare Conference(9월 3일), Wells Fargo Healthcare Conference(9월 4일), Morgan Stanley Global Healthcare Conference(9월 10일), H.C. Wainwright Global Investment Conference(9월 10일)에서 발표할 예정입니다. 파이어사이드 채팅 형식의 웹캐스트는 회사 웹사이트에서 제공되며 30일 동안 시청할 수 있습니다.
Cabaletta Bio (Nasdaq: CABA), une société biotechnologique en phase clinique développant des thérapies cellulaires ciblées à visée curative pour les maladies auto-immunes, a annoncé sa participation à quatre grandes conférences d'investisseurs en septembre 2025.
La société présentera lors de la Cantor Global Healthcare Conference (3 septembre), de la Wells Fargo Healthcare Conference (4 septembre), de la Morgan Stanley Global Healthcare Conference (10 septembre) et de la H.C. Wainwright Global Investment Conference (10 septembre). Des discussions au format "fireside chat" seront diffusées en webcast sur le site de la société et accessibles pendant 30 jours.
Cabaletta Bio (Nasdaq: CABA), ein Biotech-Unternehmen in der klinischen Phase, das kurative, zielgerichtete Zelltherapien für Autoimmunerkrankungen entwickelt, hat seine Teilnahme an vier wichtigen Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird auf der Cantor Global Healthcare Conference (3. Sept.), der Wells Fargo Healthcare Conference (4. Sept.), der Morgan Stanley Global Healthcare Conference (10. Sept.) und der H.C. Wainwright Global Investment Conference (10. Sept.) präsentieren. Webcastete Fireside-Chats werden auf der Unternehmenswebseite verfügbar sein und sind 30 Tage abrufbar.
- None.
- None.
PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in September:
- Cantor Global Healthcare Conference 2025: Webcasted fireside chat at 10:55 a.m. ET on Wednesday, September 3, 2025, in New York, NY. The Company will also be available for meetings with investors.
- 2025 Wells Fargo Healthcare Conference: The Company will be available for meetings with investors on Thursday, September 4, 2025, in Boston, MA.
- Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat at 7:45 a.m. ET on Wednesday, September 10, 2025, in New York, NY. The Company will also be available for meetings with investors.
- H.C. Wainwright 27th Annual Global Investment Conference: Webcasted fireside chat at 11:30 a.m. ET on Wednesday, September 10, 2025, in New York, NY. The Company will also be available for meetings with investors.
The webcasted fireside chats will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
FAQ
When is Cabaletta Bio (CABA) presenting at the Cantor Global Healthcare Conference 2025?
Where can I watch Cabaletta Bio's (CABA) investor conference presentations?
What type of company is Cabaletta Bio (CABA)?
Which investor conferences will Cabaletta Bio (CABA) attend in September 2025?
